Receptor News and Research

RSS

Comprehensive antibody map reveals how SARS-CoV-2 mutations evade immunity

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have created the most comprehensive map to date showing how antibodies attach to the SARS-CoV-2 virus, which causes COVID-19, and how viral mutations weaken that attachment.

21 Nov 2025

CAR T cell therapy could be a highly effective tool against atherosclerosis

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition where a build-up of plaque in the arteries reduces blood flow, leading to heart attacks and strokes.

21 Nov 2025

New neuron signaling mechanism reveals safer pathway for pain treatment

Researchers at Tulane University, with a team of colleagues from eight other universities, have discovered a new nerve cell signaling mechanism that could transform our understanding of pain and lead to safer, more effective treatments.

20 Nov 2025

Inflammatory biomarkers offer new insights for precision medicine in ischemic stroke

Ischemic stroke, a leading cause of disability and mortality worldwide, is a complex cerebrovascular event with outcomes heavily influenced by the inflammatory response.

20 Nov 2025

Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.

20 Nov 2025

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Engineered CAR-T cells show promise against glioblastoma in preclinical models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

20 Nov 2025

Fruit fly study reveals brain mechanism underlying motivation fatigue

Our brain's reward system processes and reinforces pleasurable experiences, motivating us to seek out and engage in rewarding activities ranging from eating to social interactions to recreational drug use.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025

Can black cumin help fight obesity?

...

20 Nov 2025

Breakthrough in FcγRI inhibition opens path to safer autoimmune therapies

An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI.

19 Nov 2025

Coffee protects the brain, metabolism, and immunity at the molecular level

This review uncovers the molecular networks of coffee's compounds, showcasing their antioxidant and neuroprotective effects on immunity and metabolism.

19 Nov 2025

Blood group A linked to a higher risk of primary biliary cholangitis

Findings indicate blood group A elevates the risk of primary biliary cholangitis, suggesting ABO group analysis could aid in autoimmune liver disease diagnosis.

19 Nov 2025

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Oral semaglutide delivered meaningful reductions in HbA1c and body weight among GLP-1RA-naïve adults with type 2 diabetes in a Dutch real-world cohort. Lipid levels and blood pressure showed only small changes, reflecting modest cardiometabolic effects outside glucose and weight control.

18 Nov 2025

New antibody strategy shows promise for halting cyst growth in polycystic kidney disease

Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their function, often leading to dialysis in advanced cases.

18 Nov 2025

DeepTarget tool uncovers primary and secondary drug targets across cancer types

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

18 Nov 2025

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in an individual taking tirzepatide. They found that a delta–theta biomarker disappeared during symptom-free periods and re-emerged weeks before relapse, suggesting a possible neural marker of vulnerability to dysregulated eating.

18 Nov 2025

Alzheimer’s drugs improve key cognitive skills in children with autism and low IQ

The review synthesizes evidence on whether Alzheimer’s disease medications can improve neurocognitive outcomes in children and adolescents with autism and low IQ. Across 12 studies, preliminary findings show promising gains in language, executive function, learning and memory, and general cognitive ability, particularly in younger children.

18 Nov 2025

TRPM1 loss drives rhythmic activity across retinal diseases

Rhythmic electrical activity in the retina (known as pathological oscillations) has been observed in several eye diseases, including congenital stationary night blindness (CSNB) and retinitis pigmentosa (RP).

18 Nov 2025